{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:41:42Z","timestamp":1793410902098,"version":"4.5.0"},"reference-count":113,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2975,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2007.01416.x","type":"journal-article","created":{"date-parts":[[2007,7,11]],"date-time":"2007-07-11T01:32:55Z","timestamp":1184117575000},"page":"1356-1370","source":"Crossref","is-referenced-by-count":202,"title":["Metabolic side effects of antipsychotic medication"],"prefix":"10.1155","volume":"61","author":[{"given":"A.","family":"Tschoner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Engl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Laimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rettenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. W.","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Patsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. F.","family":"Ebenbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,7,10]]},"reference":[{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(05)67483-1","article-title":"Obesity","volume":"366","author":"Haslam","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/070674370104600610","article-title":"Body mass index in persons with schizophrenia","volume":"46","author":"Coodin","year":"2001","journal-title":"Can J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4088\/JCP.v60n0402","article-title":"The distribution of body mass index among individuals with and without schizophrenia","volume":"60","author":"Allison","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1056\/NEJMoa042135","article-title":"Adiposity as compared with physical activity in predicting mortality among women","volume":"351","author":"Hu","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/CIRCULATIONAHA.105.574087","article-title":"Obesity as compared with physical activity in predicting risk of coronary heart disease in women","volume":"113","author":"Li","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.ijo.0801840","article-title":"Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia","volume":"26","author":"Thakore","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/bjp.184.1.58","article-title":"Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia","volume":"184","author":"Zhang","year":"2004","journal-title":"Br J Psychiatry"},{"issue":"Suppl. 7","key":"10.1111\/j.1742-1241.2007.01416.x-BIB9|cit9","first-page":"32","article-title":"The clinical implications of weight gain in schizophrenia","volume":"62","author":"Kurzthaler","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1176\/appi.ajp.158.10.1719","article-title":"Association of olanzapine-induced weight gain with an increase in body fat","volume":"158","author":"Eder","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/10401239809148817","article-title":"Olanzapine-induced weight gain","volume":"10","author":"Gupta","year":"1998","journal-title":"Ann Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","article-title":"Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study","volume":"157","author":"Henderson","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0924-977X(95)80001-I","article-title":"Weight gain induced by clozapine","volume":"5","author":"Hummer","year":"1995","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00002018-200124010-00005","article-title":"Bodyweight gain with atypical antipsychotics. A comparative review","volume":"24","author":"Wetterling","year":"2001","journal-title":"Drug Saf"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2007.01416.x-BIB16|cit16","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-2003-814853","article-title":"[Bodyweight in inpatients with schizophrenia]","volume":"31","author":"Wetterling","year":"2004","journal-title":"Psychiatr Prax"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.ijo.0803222","article-title":"Weight loss in overweight patients maintained on atypical antipsychotic agents","volume":"30","author":"Centorrino","year":"2006","journal-title":"Int J Obes (Lond)"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-1781(01)00234-7","article-title":"Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate","volume":"101","author":"Fontaine","year":"2001","journal-title":"Psychiatry Res"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/10401230490453293","article-title":"Atypical antipsychotic induced weight gain: pathophysiology and management","volume":"16","author":"Ananth","year":"2004","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl. 4","key":"10.1111\/j.1742-1241.2007.01416.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"449S","DOI":"10.1002\/j.1550-8528.1995.tb00212.x","article-title":"Multiple serotonin receptors: opportunities for new treatments for obesity","volume":"3","author":"Dourish","year":"1995","journal-title":"Obes Res"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2007.01416.x-BIB22|cit22","first-page":"S18","article-title":"Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine","volume":"22","author":"Heal","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB23|cit23","first-page":"361","article-title":"The concentrations of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution","volume":"20","author":"Strombom","year":"1996","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0895-4356(02)00588-7","article-title":"A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States","volume":"56","author":"Buse","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2004-815468","article-title":"Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature","volume":"37","author":"Cohen","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB27|cit27","first-page":"437","article-title":"[Diabetes mellitus after treatment with clozapine]","volume":"144","author":"Brugman","year":"2000","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1192\/bjp.171.1.90c","article-title":"Clozapine monotherapy and ketoacidosis","volume":"171","author":"Pierides","year":"1997","journal-title":"Br J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4088\/JCP.v65n0619","article-title":"A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus","volume":"65","author":"Koller","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/bmj.325.7358.243","article-title":"Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study","volume":"325","author":"Koro","year":"2002","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4088\/JCP.v64n1206","article-title":"Olanzapine induces insulin resistance: results from a prospective study","volume":"64","author":"Ebenbichler","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/01.jcp.0000155827.05327.88","article-title":"Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors","volume":"25","author":"Laimer","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","article-title":"Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis","volume":"62","author":"Henderson","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1210\/jcem.87.6.8599","article-title":"Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo","volume":"87","author":"Sowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00004850-200503000-00008","article-title":"Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine","volume":"20","author":"Brown","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4088\/JCP.v61n1006","article-title":"Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses","volume":"61","author":"Melkersson","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0006-3223(98)00100-0","article-title":"Novel antipsychotics and new onset diabetes","volume":"44","author":"Wirshing","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB39|cit39","article-title":"Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study","author":"Rettenbacher","year":"2006","journal-title":"J Psychopharmacol"},{"issue":"Suppl. 23","key":"10.1111\/j.1742-1241.2007.01416.x-BIB40|cit40","first-page":"23","article-title":"Mechanisms of antipsychotic-induced weight gain","volume":"62","author":"McIntyre","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.mp.4001729","article-title":"Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells","volume":"10","author":"Engl","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0924-977X(01)00108-0","article-title":"Different effects of antipsychotic drugs on insulin release in vitro","volume":"11","author":"Melkersson","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0924-977X(03)00072-5","article-title":"Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro","volume":"14","author":"Melkersson","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1043-2760(00)00323-4","article-title":"Free fatty acids and pathogenesis of type 2 diabetes mellitus","volume":"11","author":"Bergman","year":"2000","journal-title":"Trends Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/204748730000700505","article-title":"The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis","volume":"7","author":"Ginsberg","year":"2000","journal-title":"J Cardiovasc Risk"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1161\/01.ATV.12.11.1336","article-title":"Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state","volume":"12","author":"Patsch","year":"1992","journal-title":"Arterioscler Thromb"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s00213-006-0384-5","article-title":"Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia","volume":"186","author":"Wu","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.v63n1002","article-title":"The effects of novel antipsychotics on glucose and lipid levels","volume":"63","author":"Wirshing","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","article-title":"An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients","volume":"59","author":"Koro","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/01.yic.0000224786.75664.3b","article-title":"Early changes of plasma lipids during treatment with atypical antipsychotics","volume":"21","author":"Rettenbacher","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res"},{"issue":"Suppl. 2","key":"10.1111\/j.1742-1241.2007.01416.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"211s","DOI":"10.1002\/j.1550-8528.1995.tb00466.x","article-title":"Effect of degree of weight loss on health benefits","volume":"3","author":"Blackburn","year":"1995","journal-title":"Obes Res"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB53|cit53","first-page":"397","article-title":"Beneficial health effects of modest weight loss","volume":"16","author":"Goldstein","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000162800.64378.82","article-title":"The association of weight gain and olanzapine plasma concentrations","volume":"25","author":"Perry","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.clinthera.2005.12.005","article-title":"Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study","volume":"27","author":"Meyer","year":"2005","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/01.jcp.0000095347.32154.08","article-title":"Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone","volume":"23","author":"Weiden","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","article-title":"Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine","volume":"61","author":"Kinon","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. 4","key":"10.1111\/j.1742-1241.2007.01416.x-BIB58|cit58","first-page":"S15","article-title":"Switching approach in the management of schizophrenia patients","volume":"15","author":"Peuskens","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1176\/appi.ps.54.8.1155","article-title":"A program for managing weight gain associated with atypical antipsychotics","volume":"54","author":"Vreeland","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1547-5069.2003.00237.x","article-title":"The effects of an educational intervention on antipsychotic-induced weight gain","volume":"35","author":"Littrell","year":"2003","journal-title":"J Nurs Scholarsh"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB62|cit62","first-page":"479","article-title":"Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial","volume":"39","author":"Evans","year":"2005","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.v66n0208","article-title":"Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder","volume":"66","author":"Brar","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4088\/JCP.v67n0405","article-title":"Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial","volume":"67","author":"Kwon","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2006.01.008","article-title":"A cognitive\/behavioral group intervention for weight loss in patients treated with atypical antipsychotics","volume":"83","author":"Weber","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4088\/JCP.v65n0404","article-title":"Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program","volume":"65","author":"Menza","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"907","DOI":"10.4088\/JCP.v64n0808","article-title":"Reversal of antipsychotic-associated weight gain","volume":"64","author":"O'Keefe","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.4088\/JCP.v67n0812","article-title":"Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial","volume":"67","author":"Alvarez-Jimenez","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1007\/BF03327578","article-title":"Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance","volume":"11","author":"Gursoy","year":"2006","journal-title":"Eat Weight Disord"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jada.2005.03.010","article-title":"Medications as adjunct therapy for weight loss: approved and off-label agents in use","volume":"105","author":"Moyers","year":"2005","journal-title":"J Am Diet Assoc"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/clpt.1991.144","article-title":"Sibutramine in weight control: a dose-ranging, efficacy study","volume":"50","author":"Weintraub","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1176\/appi.ajp.162.5.954","article-title":"A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain","volume":"162","author":"Henderson","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"Suppl. 2","key":"10.1111\/j.1742-1241.2007.01416.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1055\/s-2004-828475","article-title":"[Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies]","volume":"31","author":"Himmerich","year":"2004","journal-title":"Psychiatr Prax"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00004714-200202000-00011","article-title":"The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy","volume":"22","author":"Hilger","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB75|cit75","first-page":"5","article-title":"Pharmacokinetics and drug interactions of the sedative hypnotics","volume":"37","author":"Schwartz","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB76|cit76","first-page":"14","article-title":"Orlistat in the management of antipsychotic-induced weight gain: two case reports","volume":"7","author":"Dinan","year":"2001","journal-title":"J Serotonin Res"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00004714-200210000-00014","article-title":"Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior","volume":"22","author":"Anghelescu","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.schres.2005.10.001","article-title":"A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia","volume":"82","author":"Kim","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/01.jcp.0000130556.01373.45","article-title":"Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder","volume":"24","author":"Vieta","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.wnf.0000172994.56028.c3","article-title":"Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain","volume":"28","author":"Ko","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB81|cit81","first-page":"198","article-title":"Clozapine weight gain, plus topiramate weight loss","volume":"45","author":"Dursun","year":"2000","journal-title":"Can J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1176\/ajp.156.6.968a","article-title":"Mood stabilization and weight loss with topiramate","volume":"156","author":"Gordon","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4088\/JCP.v61n0508","article-title":"Treatment of binge-eating disorder with topiramate: a clinical case series","volume":"61","author":"Shapira","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00004850-200207000-00001","article-title":"Options for pharmacological management of obesity in patients treated with atypical antipsychotics","volume":"17","author":"Werneke","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0924-977X(01)00072-4","article-title":"Effect of amantadine on weight gain during olanzapine treatment","volume":"11","author":"Floris","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euroneuro.2004.03.005","article-title":"Amantadine for weight gain associated with olanzapine treatment","volume":"15","author":"Deberdt","year":"2005","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3 Suppl. 1","key":"10.1111\/j.1742-1241.2007.01416.x-BIB87|cit87","first-page":"159","article-title":"Amantadine induces weight loss in patients treated with olanzapine","volume":"53","author":"Baruch","year":"2002","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004714-198704000-00008","article-title":"Amantadine in the treatment of neuroendocrine side effects of neuroleptics","volume":"7","author":"Correa","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/appi.ajp.162.9.1744","article-title":"Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine","volume":"162","author":"Graham","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00004714-199612000-00014","article-title":"Amantadine does not exacerbate positive symptoms in medicated, chronic schizophrenic patients: evidence from a double-blind crossover study","volume":"16","author":"Silver","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0006-3223(00)00872-6","article-title":"H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients","volume":"48","author":"Sacchetti","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0924-977X(02)00127-X","article-title":"Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial","volume":"13","author":"Cavazzoni","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/hup.514","article-title":"Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain","volume":"18","author":"Atmaca","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hup.477","article-title":"Nizatidine for the treatment of patients with quetiapine-induced weight gain","volume":"19","author":"Atmaca","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB95|cit95","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1176\/appi.ajp.159.4.655","article-title":"Metformin for weight loss in pediatric patients taking psychotropic drugs","volume":"159","author":"Morrison","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB96|cit96","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/070674370605100310","article-title":"Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial","volume":"51","author":"Baptista","year":"2006","journal-title":"Can J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4088\/JCP.v62n0813b","article-title":"Metformin in obesity associated with antipsychotic drug administration: a pilot study","volume":"62","author":"Baptista","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB98|cit98","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1111\/j.1742-1241.2007.01416.x-BIB99|cit99","first-page":"133","article-title":"Therapy of antipsychotic-associated diabetes mellitus with pioglitazone, a case series","volume":"81","author":"Edlinger","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB100|cit100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2796.2002.00936.x","article-title":"Risperidone and severe cerivastatin-induced rhabdomyolysis","volume":"251","author":"Giner","year":"2002","journal-title":"J Intern Med"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB101|cit101","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/026988110401800316","article-title":"Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin","volume":"18","author":"Webber","year":"2004","journal-title":"J Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB102|cit102","first-page":"99","article-title":"Interactions between the cytochrome P450 system and the second-generation antipsychotics","volume":"28","author":"Prior","year":"2003","journal-title":"J Psychiatry Neurosci"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB103|cit103","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0006-3223(01)01333-6","article-title":"Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin","volume":"51","author":"Furst","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB104|cit104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4 Pt 1","key":"10.1111\/j.1742-1241.2007.01416.x-BIB105|cit105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0013-7006(05)82412-1","article-title":"[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]","volume":"31","author":"Ruetsch","year":"2005","journal-title":"Encephale"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB106|cit106","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/01.jcp.0000138777.71009.61","article-title":"Effectiveness of orlistat versus diet and exercise for weight gain associated with antidepressant use: a pilot study","volume":"24","author":"Schwartz","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB107|cit107","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-3956(03)00018-9","article-title":"Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients","volume":"37","author":"Zimmermann","year":"2003","journal-title":"J Psychiatr Res"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB108|cit108","doi-asserted-by":"crossref","first-page":"981","DOI":"10.4088\/JCP.v63n1104","article-title":"Topiramate treatment for SSRI-induced weight gain in anxiety disorders","volume":"63","author":"Van Ameringen","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB109|cit109","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/ajcn\/68.4.899","article-title":"Expert panel on the identification, evaluation, and treatment of overweight in adults","volume":"68","author":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB110|cit110","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/070674370605100805","article-title":"Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications","volume":"51","author":"Faulkner","year":"2006","journal-title":"Can J Psychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB111|cit111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2002-36391","article-title":"Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives","volume":"35","author":"Baptista","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB112|cit112","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1345\/aph.1G333","article-title":"Medications associated with weight gain","volume":"39","author":"Malone","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1742-1241.2007.01416.x-BIB225|cit113","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-18571-7","volume-title":"Diabetes in der Praxis","author":"Waldh\u00e4usl","year":"2004"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2007.01416.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2007.01416.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T04:45:32Z","timestamp":1683953132000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2007.01416.x"}},"subtitle":["Metabolic side effects of antipsychotic medication"],"short-title":[],"issued":{"date-parts":[[2007,7,10]]},"references-count":113,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01416.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7,10]]}}}